Evidence map›Paper›PMID 29464579›Full record

Observational studyWorld journal of pediatrics : WJP2018

Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study.

Jiong Qin, Yi Wang, Xin-Fang Huang, Yu-Qin Zhang, Fang Fang, Yin-Bo Chen, Zhong-Dong Lin, Yan-Chun Deng, Fei Yin, Li Jiang and 2 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in World journal of pediatrics : WJP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 1 country.

Jiong QinDepartment of Pediatrics, Peking University People's Hospital, No. 11 Xi Zhi Men Nan Da Jie, Xicheng District, Beijing, 100044, China. jiongqinbeijing01@126.com.
Yi WangDepartment of Neurology, Children's Hospital, Fudan University, Shanghai, China.
Xin-Fang HuangDepartment of Pediatrics, Quanzhou Women's and Children's Hospital, Quanzhou, China.
Yu-Qin ZhangDepartment of Neurology, Tianjin Children's Hospital, Tianjin, China.
Fang FangDepartment of Neurology, Beijing Children's Hospital, Beijing, China.
Yin-Bo ChenDepartment of Pediatric Neurology, The First Bethune Hospital, Jilin University, Changchun, China.
Zhong-Dong LinDepartment of Pediatric Neurology, The 2nd Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Yan-Chun DengDepartment of Neurology, Xijing Hospital, Xi'an, China.
Fei YinDepartment of Pediatrics, Xiangya Hospital, Central South University, Changsha, China.
Li JiangDepartment of Neurology, Children's Hospital, Chongqing Medical University, Chongqing, China.
Ye WuDepartment of Pediatrics, Peking University First Hospital, Beijing, China.
Xiang-Shu HuThe third Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, China.
Beijing Children’s Hospital · CNChildren's Hospital of Chongqing Medical University · CNChildren's Hospital of Fudan University · CNFirst Bethune Hospital of Jilin University · CNGuangdong 999 Brain Hospital · CNPeking University First Hospital · CNPeking University People's Hospital · CNTianjin Children's Hospital · CNWenzhou Medical University · CNXiangya Hospital Central South University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to assess efficacy and safety of oxcarbazepine (OXC) oral suspension in pediatric patients aged 2-5 years with partial seizures (PS) and/or generalized tonic-clonic seizures (GTCS) in real-world clinical practice in China.

methodsThis 26-week, prospective, single-arm, multicenter, observational study recruited pediatric patients aged 2-5 years with PS or GTCS suitable for OXC oral suspension treatment based on physicians' judgments from 11 medical centers in China. Enrolled subjects started OXC oral suspension treatment as monotherapy or in combination with other antiepileptic drugs. Primary efficacy outcome was the percentage of pediatric subjects achieving ≥ 50% seizure frequency reduction at the end of the 26-week treatment. Secondary efficacy-related parameters and safety parameters such as adverse events (AEs) and serious AEs (SAEs) were also monitored during the 26-week treatment period.

resultsSix hundred and six pediatric patients were enrolled and 531 (87.6%) completed the study. After 26 weeks of treatment, 93.3% subjects achieved ≥ 50% seizure frequency reduction, and 81.8% achieved 100% seizure frequency reduction compared to baseline. Among different seizure types, OXC was effective in all subjects with simple PS and in > 90% of subject with other type of seizure present in the study. AEs were observed in 49 (8.1%) subjects. Only three subjects experienced SAE. Rash (n = 18, 2.97%) was the most common AE. Only 17 subjects discontinued due to AEs.

conclusionThis study, reporting the real-world data, further confirms the efficacy and good safety profile of OXC oral suspension in Chinese pediatric patients aged 2-5 years with PS and/or GTCS.

Indexed as

Administration, OralAge FactorsAnticonvulsantsCarbamazepineChild, PreschoolChinaDose-Response Relationship, DrugDrug Administration ScheduleEpilepsy, Tonic-ClonicFemaleFollow-Up StudiesHumansMaleOxcarbazepineProspective StudiesSeizuresAnticonvulsantsCarbamazepineOxcarbazepineAntiepileptic drugsGeneralized tonic–clonic seizuresOxcarbazepine oral suspensionPartial seizuresPediatric patients

Identifiers

PMID29464579
OpenAlexW2790316383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.